- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Paternal age.
Displaying page 1 of 1.
EudraCT Number: 2007-003247-70 | Sponsor Protocol Number: UZAPED1 | Start Date*: 2007-10-29 | |||||||||||
Sponsor Name:Belgian Study Group for Pediatric Endocrinology | |||||||||||||
Full Title: Efficacy and safety of a 4 year combination therapy of growth hormone and gonadotropin- releasing hormone agonist in children with a short predicted height. | |||||||||||||
Medical condition: predicted short stature | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002627-35 | Sponsor Protocol Number: TAK-667-3001 | Start Date*: 2022-07-25 |
Sponsor Name:Takeda Pharmaceutical Company Limited | ||
Full Title: A Multicenter, Open-Label, Non-randomized Phase 3 Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneous Administration of Icatibant (TAK-667) in Japanese Children and Adolescent... | ||
Medical condition: Hereditary Angioedema | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2023-001105-31 | Sponsor Protocol Number: SHP643-304 | Start Date*: 2024-04-26 |
Sponsor Name:Takeda | ||
Full Title: A Multi-center, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Lanadelumab (SHP643) in Chinese Subjects with Hereditary Angioedema | ||
Medical condition: Hereditary Angioedema (HAE) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2022-002621-98 | Sponsor Protocol Number: SHP643-302 | Start Date*: 2022-08-19 | ||||||||||||||||
Sponsor Name:Takeda | ||||||||||||||||||
Full Title: A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects with Hereditary Angioedema | ||||||||||||||||||
Medical condition: Hereditary Angioedema (HAE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000491-18 | Sponsor Protocol Number: AT-007-1005 | Start Date*: 2022-09-14 | |||||||||||
Sponsor Name:Applied Therapeutics Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Pharmacodynamic Efficacy and Clinical Benefit of AT 007 in Patients with Sorbitol Dehydrogenase (SORD) Deficiency | |||||||||||||
Medical condition: SoRbitol Dehydrogenase (SORD) DEficiency | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
